Sentiment Survey
|
|
|
|
|
|
|
|
|
|
|
|
Investment Grade:
|
|
Comments(0)
|
(0)
|
(0)
|
Ranking History
Headlines
- WBR "PharmaBiotech IP Summit," Philadelphia, May 28-30
Apr 29, 2008 01:27 AM
- Observations and Stocks for Friday
Apr 11, 2008 12:50 AM
- Endo Pharma Holdings Withdrew SNDA For Frova 2.5mg Tablets
Apr 07, 2008 06:36 PM
- Endo And Penwest File Lawsuit Against Actavis Over Opana
Mar 28, 2008 06:04 PM
- Endo And Penwest File Lawsuit Against Actavis Over Opana
Mar 28, 2008 06:04 PM
- STREET MOVES: Two Friedman Billings Analysts Leave Firm
Feb 08, 2008 10:47 AM
- Endo, Alexza Pharmaceutical In AZ-003 Development, Licensing Pact
Dec 27, 2007 04:29 PM
- Endo, Alexza Pharmaceutical In AZ-003 Development, Licensing Pact
Dec 27, 2007 04:29 PM
- Zingo Approval Makes Anesiva Appealing Acquisition Target for Endo Pharma
Aug 17, 2007 07:52 PM
- NASDAQ Technical Picture - Price Pivots at Gap Support
Jul 12, 2007 02:22 AM
- Endo Announces Resignation of Board Member
Dec 01, 2008 04:30 PM
- Endo Pharmaceuticals Announces Acceptance of UBS AG Settlement Offer Relating to Auction Rate Securities
Nov 17, 2008 08:49 AM
- Endo Pharmaceuticals Reports Strong Third Quarter Financial Results
Oct 30, 2008 07:55 AM
- Endo Pharmaceuticals to Hold Conference Call and Webcast on Third Quarter 2008 Financial Results
Oct 13, 2008 04:30 PM
- Endo Pharmaceuticals Announces Resignation of Chief Financial Officer
Sep 02, 2008 04:30 PM
- Endo Pharmaceuticals Appoints Dr. Sandeep Gupta, Senior Vice President, Discovery and Early Development
Aug 11, 2008 12:00 PM
- Endo Pharmaceuticals Reports Strong Second Quarter Financial Results
Jul 31, 2008 07:04 AM
- Endo Pharmaceuticals to Hold Conference Call and Webcast on Second Quarter 2008 Financial Results
Jul 22, 2008 09:00 AM
- Endo Pharmaceuticals Appoints Blaine T. Davis as Vice President, Investor Relations and Corporate Communications
May 22, 2008 09:06 AM
- LPGA Tour Pro Diana D'Alessio Takes Swing at Menstrual Migraines
May 15, 2008 08:02 AM
Analyst Ratings
|
|
Share Performance
|
Period
|
ENDP
|
Compare to S&P
|
| YTD |
-17.85 %
|
-0.01 %
|
| 4 Weeks |
13.52 %
|
24.22 %
|
| 12 Weeks |
4.73 %
|
48.19 %
|
|
Financial Ratios
Earnings Performance
|
EPS Growth in Last Quarter: 7.02 %
|
|
EPS Growth in Last Year: 38.64 %
|
|
Sales Growth in Last Quarter: 3.46 %
|
|
Sales Growth in Last Quarter: 17.55 %
|
|
|
